A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Moderate to Severe Chronic Plaque PsoriasisPsoriatic ArthritisChronic Plaque Psoriasis
- Interventions
- Other: Placebo
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 435
- Registration Number
- NCT03410992
- Locations
- 🇵🇱
Ps0013 361, Białystok, Poland
🇷🇺Ps0013 402, Moscow, Russian Federation
🇵🇱Ps0013 359, Katowice, Poland
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Conditions
- Moderate to Severe Chronic Plaque PsoriasisChronic Plaque PsoriasisPsoriatic Arthritis
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 567
- Registration Number
- NCT03370133
- Locations
- 🇭🇺
Ps0009 253, Orosháza, Hungary
🇯🇵Ps0009 607, Chiyoda, Japan
🇯🇵Ps0009 620, Hamamatsu, Japan
Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 406
- Registration Number
- NCT03370120
- Locations
- 🇺🇸
Ep0093 645, Golden Valley, Minnesota, United States
🇺🇸Ep0093 806, Hackensack, New Jersey, United States
🇺🇸Ep0093 802, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis
- First Posted Date
- 2017-11-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 255
- Registration Number
- NCT03355573
- Locations
- 🇵🇱
As0009 453, Elblag, Poland
🇨🇿As0009 201, Praha 4, Czechia
🇵🇱As0009 460, Wroclaw, Poland
A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 184
- Registration Number
- NCT03347110
- Locations
- 🇨🇿
Pa0009 205, Brno, Czechia
🇨🇿Pa0009 207, Olomouc, Czechia
🇺🇸Pa0009 013, Mesquite, Texas, United States
A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures
- Conditions
- Electroencephalographic Neonatal Seizures
- Interventions
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 9
- Registration Number
- NCT03325439
- Locations
- 🇨🇿
N01349 205, Praha, Czechia
🇧🇪N01349 204, Leuven, Belgium
🇫🇷N01349 207, Lille, France
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
- Conditions
- Partial Seizures With or Without Secondary GeneralizationEpilepsy
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 207
- Registration Number
- NCT03250377
- Locations
- 🇨🇳
Ep0085 905, Beijing, China
🇨🇳Ep0085 901, Chengdu, China
🇨🇳Ep0085 902, Guangzhou, China
A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
- Conditions
- Hidradenitis Suppurativa
- Interventions
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 90
- Registration Number
- NCT03248531
- Locations
- 🇺🇸
Hs0001 115, Las Vegas, Nevada, United States
🇧🇪Hs0001 203, Brussels, Belgium
🇳🇴Hs0001 701, Harstad, Norway
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 43
- Registration Number
- NCT03230292
- Locations
- 🇦🇺
Ps0018 101, Carlton, Australia
🇨🇦Ps0018 201, Ajax, Canada
🇦🇺Ps0018 103, East Melbourne, Australia
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
- Conditions
- Ankylosing Spondylitis
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 76
- Registration Number
- NCT03215277
- Locations
- 🇬🇷
As0013 406, Thessaloníki, Greece
🇵🇱As0013 708, Białystok, Poland
🇵🇱As0013 709, Kraków, Poland